Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1 beta levels

Yalcin A. D., ÇİLLİ A., Bisgin A., Strauss L. G., Herth F.

EXPERT OPINION ON BIOLOGICAL THERAPY, vol.13, no.9, pp.1335-1341, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13 Issue: 9
  • Publication Date: 2013
  • Doi Number: 10.1517/14712598.2013.819338
  • Journal Name: EXPERT OPINION ON BIOLOGICAL THERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1335-1341
  • Keywords: 25-hydroxyvitamin D, asthma, cardiovascular risk, CXCL8, IL-1 beta, omalizumab, protein C and S deficiency, sCD200, PERSISTENT ALLERGIC-ASTHMA, EXHALED NITRIC-OXIDE, QUALITY-OF-LIFE, ANTI-IGE, IMMUNOGLOBULIN, STRAIL
  • Akdeniz University Affiliated: Yes

Abstract

Background: There have been concerns about the cardiovascular safety of omalizumab.